



PRESS RELEASE

27 February 2009

ENIGMA DIAGNOSTICS FINALIST IN 2009 INTERNATIONAL HEALTHCARE ASSOCIATED INFECTIONS AWARDS

Porton Down, UK – Enigma Diagnostics, the decentralised and point-of-care molecular diagnostics company, announces that the Enigma ML (mini laboratory) was nominated as a finalist in 2009 International Healthcare Associated Infections Awards for the most innovative technologies to prevent healthcare associated infections. The awards were presented by the UK Department of Health, supported by NHS Purchasing and Supply Agency (NHS PASA) and the Association of British Healthcare Industries (ABHI).

Enigma is developing a rapid, point-of-care diagnostic system for screening and diagnosis of healthcare associated infections, including MRSA and *Clostridium difficile*, two of the leading, avoidable causes of illness and death in hospitals. The system consisting of instrumentation, tests and reagents will rapidly detect MRSA and *Clostridium difficile* DNA from swab samples at the point of care.

-ENDS-



PRESS RELEASE

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com